📊 Key Data
  • $1.2B: Estimated annual revenue potential for Noom's new OpenRx peptide therapies in the cash-pay longevity market.
  • 6 Peptides: Initial OpenRx formulary includes sermorelin, NAD+, oxytocin, PT-141, and tadalafil combinations.
  • 503A Pharmacies: All compounded medications are prepared by state-licensed facilities under FDA's Section 503A.
🎯 Expert Consensus

Experts agree Noom's pivot to cash-pay peptides represents a high-risk, high-reward strategy that capitalizes on surging longevity demand but faces significant regulatory and scientific scrutiny.

about 5 hours ago
Beyond Weight Loss: Noom Pivots to Cash-Pay Peptides With OpenRx

Beyond Weight Loss: Noom Pivots to Cash-Pay Peptides With OpenRx

PRINCETON, N.J. – November 17, 2026 — For years, Noom was synonymous with a psychology-first approach to weight loss, utilizing a digital app to coax users into healthier habits. But as the digital health landscape rapidly evolves, so too does the company's ambition. Today, the telehealth provider announced the launch of OpenRx, a direct-to-consumer brand that plunges the company headfirst into one of the most lucrative and legally complex sectors of modern wellness: clinician-prescribed peptide therapies and preventive health formulations.

The launch marks a definitive shift in the digital health sector's broader strategy. OpenRx debuts with a suite of compounded medications targeted squarely at the anti-aging and lifestyle optimization market. The initial formulary includes injectable sermorelin for muscle support, injectable NAD+ for cellular energy, and two oral dissolvable tablet (ODT) formulations focused on sexual health and intimacy, combining peptides like oxytocin and PT-141 with tadalafil.

Operating independently from its parent company's intensive behavioral modification programs, the new brand allows consumers to access these therapies without mandatory participation in core app curricula. It is a bold expansion into the cash-pay longevity market, a space characterized by surging consumer demand, high profit margins, and intense regulatory scrutiny.

Beyond the Scale: The Pivot to Cash-Pay Longevity

The commercial incentives driving this pivot are impossible to ignore. Over the past three years, the explosion of GLP-1 receptor agonists for weight loss fundamentally altered the economics of digital health. Companies that previously relied on subscription-based coaching models quickly pivoted to telehealth prescribing to capture the massive demand for drugs like semaglutide and tirzepatide. Noom was no exception, launching Noom Med to integrate clinical care with its behavioral platform.

However, the GLP-1 boom brought its own set of challenges, including severe supply chain shortages, shifting insurance coverage, and mounting competition. In response, digital health platforms are aggressively diversifying into cash-pay, out-of-pocket therapeutics where margins are predictable and insurance red tape is non-existent. The longevity and functional medicine sectors—fueled by a cultural fascination with "biohacking" and proactive aging—offer the perfect frontier.

"Peptides are an important portion of the formulary of healthy aging," said Geoff Cook, CEO of Noom, in a statement today. "OpenRx enables our flagship Noom brand to deepen into cardiometabolic health while the new brand OpenRx supports patients with conditions too often neglected by traditional care models, like energy, muscle composition, skin health, sexual health, sleep, and recovery. Together both brands support the same mission: to empower everyone, everywhere to live better longer – every day."

By launching a dedicated brand, the company is positioning itself to compete directly with platforms like Ro, Hims & Hers, and specialized longevity clinics like Lifeforce. These competitors have already demonstrated the immense consumer appetite for personalized, direct-to-consumer treatments for hair loss, sexual dysfunction, and hormone optimization. OpenRx takes this a step further by mainstreaming injectable peptides, moving treatments once confined to niche anti-aging clinics onto a national, app-adjacent platform.

The Peptide Paradox and Regulatory Gray Areas

While the business case for OpenRx is clear, the regulatory environment it is stepping into is notoriously murky. The FDA has maintained a highly critical posture toward the mass-market compounding of peptides, frequently issuing warning letters regarding unapproved new drug claims and the use of unapproved bulk drug substances.

None of the compounded medications offered by OpenRx are FDA-approved in their current forms. Instead, they are prepared by state-licensed 503A compounding pharmacies. Under Section 503A of the Food, Drug, and Cosmetic Act, these facilities can legally compound medications based on individual patient prescriptions, provided they use ingredients that comply with United States Pharmacopeia (USP) monographs, are components of FDA-approved drugs, or appear on the FDA's specific 503A Bulks List.

The regulatory status of OpenRx's initial offerings highlights this complexity. Sermorelin, for instance, was once an FDA-approved drug for pediatric growth hormone deficiency but was discontinued by its manufacturer in 2008 for commercial reasons. Because it was not withdrawn for safety concerns, its active ingredient remains available for compounding, though its widespread use for adult muscle support and anti-aging is entirely off-label. Injectable NAD+, despite its popularity in wellness circles, is not an FDA-approved drug, and the FDA's Pharmacy Compounding Advisory Committee previously voted against adding it to the bulk ingredients list.

The most revealing aspect of today's announcement, however, is the company's forward-looking pipeline. OpenRx explicitly stated it is reviewing BPC-157 and TB-500 for future inclusion. Both synthetic peptides have amassed a cult following for purported tissue healing and recovery benefits, despite a historic lack of robust human clinical trials.

Until very recently, the FDA categorized both BPC-157 and TB-500 as "Category 2" substances, signaling significant safety risks and a threat of enforcement action against compounding pharmacies. But in a pivotal shift just weeks ago, on October 28, 2026, the Department of Health and Human Services (HHS) issued an interim enforcement discretion policy. This policy created a temporary, highly conditional pathway for 503A pharmacies to compound six specific peptides, including BPC-157 and TB-500, without facing immediate federal enforcement.

"Everyone deserves access to cutting-edge therapies that are appropriate for them," said Dr. Jeffrey Egler, Chief Medical Officer of Noom. "Each therapy offered by OpenRx is selected because our clinical team and I believe it is appropriate for improving patient health. We are currently reviewing BPC-157 and TB-500 as part of our ongoing process of evaluating emerging treatments for inclusion in our formulary."

Dr. Egler noted that this process involves ensuring a compliant supply chain, sourcing of active pharmaceutical ingredients (APIs), and setting up processes for adverse event reporting—all of which are strict requirements under the new HHS interim policy.

Clinical Reality vs. Wellness Momentum

Despite the regulatory opening, the scientific community remains divided on the widespread consumer use of these compounds. Academic pharmacologists and longevity researchers frequently point out that while animal models show promise—particularly for BPC-157's regenerative properties—comprehensive, large-scale human clinical trials demonstrating definitive benefits and long-term safety for healthy adults are still lacking.

Similarly, while oxytocin plays a well-documented role in social bonding, and PT-141 (bremelanotide) is FDA-approved for specific female sexual desire disorders, the efficacy and safety of compounding these with tadalafil for general sexual wellness in healthy adults requires independent clinical validation.

Industry watchdogs express concern that direct-to-consumer telehealth models may inadvertently prioritize consumer demand over clinical necessity. One healthcare regulatory analyst, who closely monitors the compounding space, noted that the presence of an illicit "gray market" for research-grade peptides sold online has pressured regulators and legitimate companies alike. By offering these compounds through a regulated 503A pharmacy network, platforms like OpenRx argue they are providing a safer alternative to the black market, ensuring USP compounding standards and proper API sourcing.

"At Noom, we've seen firsthand how action towards behavior change inspires momentum towards health," Cook explained in the press release. "For just as many, we've also seen it work the other way around, where a treatment sparks the momentum that drives action towards behavior change. OpenRx meets people where they are, makes responsible care easier to navigate, and helps people take practical steps toward healthier living."

This philosophy—that a pharmaceutical catalyst can jumpstart lifestyle modifications—is becoming the prevailing ethos of modern digital health. It represents a fundamental departure from the restrictive diet-and-exercise dogmas of the past decade. Yet, as digital health platforms transform into virtual longevity clinics, they must navigate a delicate balance. They are tasked with scaling access to cutting-edge, in-demand therapies while operating within a regulatory framework that is still scrambling to catch up to the realities of modern preventative medicine.

Topics & Related

Event:
Product Launch
Theme:
Telehealth & Digital Health
Sector:
Telehealth
Pharmaceuticals
Product:
Pharmaceuticals & Therapeutics

📝 This article is still being updated

Are you a relevant expert who could contribute your opinion or insights to this article? We'd love to hear from you. We will give you full credit for your contribution.

Contribute Your Expertise →
UAID: 55200